Pattern of Relapse after Fractionated External Beam Radiotherapy for Meningioma: Experience from Addenbrooke's Hospital

• Published in: Clinical oncology (Royal College of Radiologists (Great Britain)) Vol. 21; no. 10; pp. 745 - 752
• Main Authors: Estall, V, Treece, S.J, Jena, R, Jefferies, S.J, Burton, K.E, Parker, R.A, Burnet, N.G
• Format: Journal Article
• Language: English
• Published: England 01.12.2009
• Subjects: Adult; Aged; Aged, 80 and over; Female; Hematology, Oncology and Palliative Medicine; Hospitals; Humans; Male; Meningeal Neoplasms - mortality; Meningeal Neoplasms - radiotherapy; Meningioma - mortality; Meningioma - radiotherapy; Middle Aged; Neoplasm Recurrence, Local - epidemiology; Radiology; Radiotherapy - methods; Retrospective Studies; Survival Rate; Young Adult; meningioma; radiotherapy; Local control
• ISSN: 0936-6555; 1433-2981
• DOI: 10.1016/j.clon.2009.08.013

Abstract Aims Radiotherapy is an important treatment modality for meningioma. We aimed to review the clinical outcomes for meningioma patients treated with radiotherapy in the Addenbrooke's Hospital Oncology Department. Materials and methods A retrospective chart review was carried out on patients with meningioma referred and treated in the department between 1 November 1996 and 31 October 2006. Patient details and outcomes were recorded and the results were analysed to assess survival outcomes. Survival data were confirmed by the Eastern Cancer Registration and Information Centre. Results In total, 174 patients were referred to the department for an oncology opinion. Of these, 128 proceeded to radiotherapy. The median follow-up was 5.3 years (range 2.1–11.9 years). Sixty-seven per cent of the patients were older than 50 years, and the female: male ratio was 2.2: 1. Overall survival was 78% at the time of follow-up, with death related to meningioma in 7% of the total cohort. Local control was 85% overall, 93% for grade 1 disease, 45% for grade 2 disease and 82% for grade 3 disease. Patients with non-benign disease were more likely to receive >50 Gy (27% of grade 1 lesions vs 65% of grade 2/3 lesions), but despite this local control remained poor, even with the higher dose delivered (local control 60 and 40% for grade 2 lesions treated with 50 and >50 Gy, respectively, and 100 and 75% for grade 3 lesions treated with 50 and >50 Gy, respectively). Conclusions Our cohort of patients had an overall local control and survival similar to those documented from other departments. Grade was an important prognostic factor. Patients treated with >50 Gy had worse local control outcomes, probably due to selection bias. Dose escalation may still be appropriate for high-risk disease, and may be more effective with more conformal techniques, such as intensity-modulated radiotherapy.